Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
WO2021080359A1
Bicyclic compound and use thereof
WO2021080313A1
Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability
WO2021080312A1
Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function
WO2021066578A1
Bicyclic compound and use thereof
US10611737B1
Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
WO2020080866A1
Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
US2020046674A1
Aminocarbonylcarbamate compounds
CA3113052A1
Use of carbamate compound for prevention, alleviation, or treatment of concurrent seizures
WO2020060251A1
Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
TW202023547A
Compound having oxadiazole and pharmaceutical composition containing the same
EP3768257A1
Use of [(1r)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
EP3711761A1
Use of carbamate compound for reducing or treating developmental disorders including fragile x syndrome, angelman syndrome or rett syndrome
KR20200074153A
Use of carbamate compounds for the prevention, alleviation or treatment of epilepsy with or without epileptic seizures
KR20200074152A
Use of carbamate compounds to prevent or treat diseases associated with an increase in late sodium current
US2020368203A1
Use Of A Carbamate Compound To Prevent, Alleviate Or Treat Visceralgia Or Pain Arising From Visceral Disease
KR20200074157A
A combination for the prevention, alleviation or treatment of schizophrenia comprising carbamate compounds
WO2019098632A1
Use of carbamate compound for preventing, alleviating or treating myotonia
